CIK 0001590560
- Large accelerated filer
uniQure N.V.
Sign in to watch- Ticker
- QURE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +1 339-970-7000
- Business address
- PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP
- Former names
- uniQure B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $192,950
- in 1 filing, $193K under 10b5-1 plans
Net −$192,950. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | Meek David D. Director | Sale 10b5-1 | −9,080 | $21.25 | $193K | 30,667 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −9,200 | $44.43 | $409K | 531,109 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −4,282 | $45.43 | $195K | 526,827 |
| 2026-07-02 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −7,600 | $45.89 | $349K | 519,227 |
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −10,000 | $46.46 | $465K | 168,235 |
| 2026-06-30 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −20,000 | $46.40 | $928K | 148,235 |
| 2026-06-30 | Kaye Jack Director | Sale 10b5-1 | −4,107 | $46.49 | $191K | 25,996 |
| 2026-06-30 | Kaye Jack Director | Sale 10b5-1 | −17,060 | $46.43 | $792K | 25,996 |
| 2026-06-26 | Abi-Saab Walid Chief Medical Officer | Sale | −1,434 | $46.86 | $67K | 168,235 |
| 2026-06-25 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −28,716 | $50.02 | $1.4M | 519,227 |
| 2026-06-24 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −6,696 | $50.00 | $335K | 519,227 |
| 2026-06-18 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −4,656 | $50.00 | $233K | 558,810 |
| 2026-06-18 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −37,015 | $50.00 | $1.9M | 521,795 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −23,977 | $42.61 | $1.0M | 699,262 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −6,023 | $43.70 | $263K | 693,239 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −32,581 | $45.02 | $1.5M | 660,658 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −56,929 | $43.43 | $2.5M | 603,729 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −33,334 | $45.01 | $1.5M | 570,395 |
| 2026-06-17 | Kapusta Matthew C CEO, Managing Director | Sale 10b5-1 | −11,585 | $48.65 | $564K | 558,810 |
| 2026-06-17 | Balachandran Madhavan Director | Sale 10b5-1 | −5,295 | $47.08 | $249K | 49,644 |
Page 1 of 6 · 110 trades